Novel Treatment Approaches in the Management of Renal Cell
Carcinoma (RCC): A Closer Look at Advances in Immunotherapy
in an Evolving Treatment Paradigm

 

A continuing medical education activity sponsored by NAMCP and AAMCN 

Novel Treatment Approaches in the Management of Renal Cell Carcinoma (RCC): A Closer Look at
Advances in Immunotherapy in an Evolving Treatment Paradigm is a 3-part webcast series that will
explore the latest clinical advances and recent data the treatment and management of RCC.

 By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all 3 or in order.

These are archives of live webinars held between July 26, 2019 and August 9, 2019.
If you participated in any of the live webinars, you are not eligible to claim credit from the archive of that webinar.

 Each session has its own specific valid dates

This series is supported by an educational grant from Merck Sharp & Dohme Corp.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

 Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
Managed Care and clinical decision-making in the setting of advanced renal cell carcinoma (RCC) has been undergoing dramatic change in the past few years. The approval of new immunotherapeutic agents has expanded the lines of therapy available to patients, especially around combination options, and raised questions about how rational treatment planning and effective sequencing of new and older standards of care can optimize patient outcomes. Additionally, the benefit of real-world experience and data from subgroup analyses and long-term follow-up of landmark clinical trials continue to refine treatment strategies in advanced RCC.


Improving Patient Adherence and Quality of Life in Advanced Renal Cell Carcinoma (RCC): Anticipating and Managing Immune-Related Adverse Events

  1. Discuss challenges to patient adherence and quality of life when utilizing immunotherapy in advanced RCC
  2. Explore strategies to monitor and manage adverse events associated with immunotherapies and immunotherapy combination options in advanced RCC in order to improve patient adherence and quality of life
  3. Review recent clinical trial data around the safety of immunotherapies in advanced RCC, both alone and in combination, and their effect on patient quality of life
  4. Identify patients with advanced RCC who would potentially benefit from, and be able to tolerate, immunotherapies, either alone or in combination
       Physician, Nursing and CMCN credits valid to October 1, 2021

A Deeper Look into Immunotherapies in the Management of Advanced Renal Cell Carcinoma (RCC): Emerging Combination Options in an Evolving Treatment Paradigm

  1. Identify current unmet clinical needs in the management of advanced renal cell carcinoma (RCC) and evidence-based recommendations for the care of patients with these tumors
  2. Review the efficacy and safety of approved and emerging immunotherapies in the management of advanced RCC
  3. Examine recent clinical trial data on immunotherapy combination options in the management of advanced RCC
  4. Analyze strategies to optimally sequence immunotherapy in advanced RCC management
  5. Identify patients with advanced RCC who would potentially benefit from immunotherapies, either alone or in combinationdentify the unmet clinical needs resulting from ineffective preventive treatments in migraines
       Physician, Nursing and CMCN credits valid to October 1, 2021

What Does Managed Care Need to Know about Immunotherapies in the Management of Advanced Renal Cell Carcinoma (RCC)?

  1. Examine the impact advanced RCC has on pharmacoeconomics and total cost of patient care in oncology
  2. Discuss the managed care considerations of current and emerging immunotherapies and combinations by exploring where these agents fit into the current advanced RCC management paradigm
  3. Apply methods to enable optimal cost management of immunotherapies to be realized by multiple RCC stakeholders, including managed care organizations
  4. Explore interventions to coordinate health plan and affiliated provider's efforts that will lead to better outcomes for patients with advanced RCC
       Physician, Nursing and CMCN credits valid to October 1, 2021